Prat-
1. It is tempting to notice that all oncological outcomes are favored in the hypofractionated group, but statistical significance is a function of sample size. So, for example, the difference in overall survival was 11%. That was based on 75% in the Hypo group of 85 men, and 64% in the Conv group of 83 men. Statistically, one can have only 88% confidence that that difference would be non-zero in the entire population. 88% might sound pretty good, but, by convention, we all agree that 95% confidence is needed. The overall survival would have had to be at least 78% in the Hypo group to be statistically significant.
Here's an online calculator if you want to play with it:
/www.medcalc.org/calc/comparison_of_proportions.php2. In the US, it's probably being done to some extent at the institutions where they did the trials: Fox Chase, Cleveland Clinic, MD Anderson, and the 300 or so institutions that participated in RTOG 0415. ASTRO has not issued a policy directive. NCCN makes the following statement:
"Moderately hypofractionated image-guided IMRT regimens (2.4–4 Gy per fraction over 4-6 weeks) have been tested in randomized trials, and its efficacy has been similar or non-inferior to conventionally fractionated IMRT. Toxicity was similar between moderately hypofractionated and conventional regimens in many, but not all of the trials. These RT techniques can be considered as an alternative to conventionally fractionated regimens when clinically indicated."
There have been a few trials of moderate hypofraction for SRT.